Enterome bolsters board with new executive appointment

pharmafile | July 12, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  Enterome, biotech, drugs, healthcare, pharma, pharmaceuticals 

Enterome, a clinical-stage company specialising in the personalised treatment of microbiome-related diseases based in Paris, France, has announced the appointment of Mary Thistle to its board as a non-Executive Director.

Thistle currently serves as the Chief Operating Officer of Dimension Therapeutics, a metabolic and rare disease specialist biopharmaceutical firm focusing on ailments of the liver, which she joined in 2015. Before this, she held the role of Senior Vice President, Business Development at Cubist Pharmaceuticals, and it was here that she oversaw the execution of four major acquisitions, including Trius Therapeutics and Optimer Pharmaceuticals – two companies which were acquired by Cubist Pharmaceuticals in 2013, which was itself acquired by MSD for $9.5 billion a year later.

“We are pleased to welcome Mary to the Enterome Board,” commented Georges Gemayel, Non-Executive Chairman of Enterome. “This is an exciting period for the Company and we are confident that Mary’s experience will be a valuable asset assisting us to achieve our goals.”

Thistle herself added: “I am honoured to join the Enterome board and look forward to working with the management team to help the Company capitalize on its world-leading position in understanding the microbiome to create novel therapies for microbiome-related diseases.”